Stoke Therapeutics (STOK) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$27.6M

Revenue (quarter)

$9.3M

Revenue growth (year over year)

−32.51%

Gross profit (trailing twelve months)

$27.6M

Gross margin

100.00%

Net income (trailing twelve months)

−$207.9M

Net income (quarter)

−$61.6M

Net income growth (year over year)

−162.39%

Net margin

−753.60%

Return on equity

−61.10%

EPS (trailing twelve months)

−$3.39

Book value per share

$5.54

P/E (trailing twelve months)

—

Price to book

4.28

Debt to assets

12.29%

Payout ratio

—

Dividend yield

—

Company profile

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the bodys potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

• Is Stoke Therapeutics (STOK) profitable?

  No. Stoke Therapeutics reported a net loss of $207.9M over the trailing twelve months.

• How much revenue does Stoke Therapeutics (STOK) make?

  Stoke Therapeutics generated $27.6M in revenue over the trailing twelve months, down 32.51% year over year.

• How do I buy stock in Stoke Therapeutics (STOK)?

  STOK trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.